Company Description
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.
It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology.
It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories.
The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews.
It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc.
The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022.
GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Country | GB |
IPO Date | Mar 28, 1980 |
Industry | Drug Manufacturers - General |
Sector | Healthcare |
Employees | 70,212 |
CEO | Emma Natasha Walmsley |
Contact Details
Address: 980 Great West Road Brentford, GB | |
Website | https://www.gsk.com |
Stock Details
Ticker Symbol | GSK |
Exchange | NYSE |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001131399 |
CUSIP Number | 37733W204 |
ISIN Number | US37733W2044 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Emma Natasha Walmsley | Chief Executive Officer & Director |
Sally Jackson | Senior Vice President of Global Communications & Chief Executive Officer Office |
Diana Conrad | Chief People Officer |
Julie Belita Brown A.C.A. | Chief Financial Officer & Executive Director |
David Simon Redfern BSc (Hons), CA | President of Corporate Development |
James Ford | Senior Vice President & Group General Counsel of Legal & Compliance |
Philip C. Thomson | President of Global Affairs |
Sarah Elton-Farr | Head of Investor Relations |
Shobie Ramakrishnan | Chief Digital & Technology Officer |
Tony Wood | Chief Scientific Officer and Head of R&D |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 12, 2024 | 6-K | Filing |
Dec 09, 2024 | 6-K | Filing |
Dec 09, 2024 | 6-K | Filing |
Dec 09, 2024 | 6-K | Filing |
Dec 05, 2024 | 6-K | Filing |
Dec 02, 2024 | 6-K | Filing |
Dec 02, 2024 | 6-K | Filing |
Nov 27, 2024 | 6-K | Filing |
Nov 25, 2024 | 6-K | Filing |
Nov 22, 2024 | 6-K | Filing |